Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts
Cancer immunotherapy involves the use of the immune system for cancer treatment. Recently, immune checkpoint-blocking antibodies have become integral for the treatment of some cancers. However, small molecules exhibit advantages over monoclonal antibody drugs, such as cell penetration, long half-lif...
Guardado en:
Autores principales: | Yoshihide Suzuki, Keisuke Ichinohe, Akihiro Sugawara, Shinya Kida, Shinya Murase, Jing Zhang, Osamu Yamada, Toshio Hattori, Yoshiteru Oshima, Haruhisa Kikuchi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5446e2a977fb434dabf63311a85d4f08 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
por: Alimohammadi R, et al.
Publicado: (2020) -
CTLA-4 blockade in the treatment of colorectal cancer with microsatellite instability
por: Diana Russo, et al.
Publicado: (2021) -
Lupus susceptibility region containing CTLA4 rs17268364 functionally reduces CTLA4 expression by binding EWSR1 and correlates IFN-α signature
por: Yuan-yuan Qi, et al.
Publicado: (2021) -
INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
por: I. O. Chikileva, et al.
Publicado: (2019) -
Anti-Inflammatory Activity of an Indole Alkaloid Isolated from Bebuas (Premna serratifolia)
por: Muhaimin Muhaimin, et al.
Publicado: (2021)